Nuclear receptors and the Warburg effect in cancer

International Journal of Cancer

Volumn 137, Issue 7, 2015, Pages 1519-1527

  Thorne, James L ^a   Campbell, Moray J ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

cancer; energy regulation; nuclear receptors; Warburg effect

Indexed keywords

ADENOSINE TRIPHOSPHATE; CELL NUCLEUS RECEPTOR; GLUCOSE; GLUCOSE TRANSPORTER; HEXOKINASE; HEXOKINASE II; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN KINASE B; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; CELL RECEPTOR;

CANCER DIAGNOSIS; CANCER THERAPY; CELL METABOLISM; GENE CONTROL; GENE EXPRESSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; WARBURG EFFECT; ANIMAL; ENERGY METABOLISM; METABOLISM; NEOPLASM;

ANIMALS; ENERGY METABOLISM; HUMANS; NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84902229709     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29012     Document Type: Review

References (135)

1. Hollenberg AN,. Metabolic health and nuclear-receptor sensitivity. New Engl J Med 2012; 366: 1345-7.
2. Perissi V, Rosenfeld MG,. Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 2005; 6: 542-54.
3. Yang X, Lamia KA, Evans RM,. Nuclear receptors, metabolism, and the circadian clock. Cold Spring Harb Symp Quant Biol 2007; 72: 387-94.
4. Battaglia S, Maguire O, Campbell MJ,. Transcription factor co-repressors in cancer biology: roles and targeting. Int J Cancer 2010; 126: 2511-19.
5. Makishima M, Lu TT, Xie W, et al., Vitamin D receptor as an intestinal bile acid sensor. Science 2002; 296: 1313-16.
6. Close AF, Rouillard C, Buteau J,. NR4A orphan nuclear receptors in glucose homeostasis: a minireview. Diabetes Metab 2013; 39: 478-84.
7. Baek SH, Kim KI,. Emerging roles of orphan nuclear receptors in cancer. Annu Rev Physiol 2014; 76: 177-95.
8. Evans RM, Mangelsdorf DJ,. Nuclear receptors, RXR, and the big bang. Cell 2014; 157: 255-66.
9. Long MD, Thorne JL, Russell J, et al., Cooperative behavior of the nuclear receptor superfamily and its deregulation in prostate cancer. Carcinogenesis 2014; 35: 262-71.
10. Heiden MGV, Cantley LC, Thompson CB,. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33.
11. Amoedo ND, Valencia JP, Rodrigues MF, et al., How does the metabolism of tumour cells differ from that of normal cells. Biosci Rep 2013; 33: 865-73.
12. Zheng J,. Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (review). Oncol Lett 2012; 4: 1151-7.
13. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70.
14. DeBerardinis RJ, Mancuso A, Daikhin E, et al., Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007; 104: 19345-50.
15. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
16. Vander Heiden MG, Cantley LC, Thompson CB,. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33.
17. Warburg O, Wind F, Negelein E,. The metabolism of tumors in the body. J Gen Physiol 1927; 8: 519-30.
18. Cori CF, Cori GT,. The carbohydrate metabolism of tumors. II. Changes in the sugar, lactic acid, and co-combing power of blood passing through a tumor. J Biol Chem 1925; 65: 397-405.
19. Warburg O,. Origin of cancer cells. Science 1956; 123: 309-14.
20. Hoh C,. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy- d -glucose. J Comput Assist Tomogr 1993; 17: 582-9.
21. Calcinotto A, Filipazzi P, Grioni M, et al., Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res 2012; 72: 2746-56.
22. Vazquez A, Liu J, Zhou Y, et al., Catabolic efficiency of aerobic glycolysis: the Warburg effect revisited. BMC Syst Biol 2010; 4: 58.
23. Joost HG, Bell GI, Best JD, et al., Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol 2002; 282: E974-E6.
24. Macdougald OA, Lane MD,. Transcriptional regulation of gene-expression during adipocyte differentiation. Annu Rev Biochem 1995; 64: 345-73.
25. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E,. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004; 64: 2627-33.
26. Younes M, Juarez D, Lechago LV, et al., Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res 2001; 21: 575-8.
27. Younes M, Brown RW, Stephenson M, et al., Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997; 80: 1046-51.
28. Haber RS, Weiser KR, Pritsker A, et al., GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid 1997; 7: 363-7.
29. Younes M, Brown RW, Mody DR, et al., GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res 1995; 15: 2895-8.
30. Yun JY, Rago C, Cheong I, et al., Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009; 325: 1555-9.
31. Godoy A, Ulloa V, Rodriguez F, et al., Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 2006; 207: 614-27.
32. Binder C, Binder L, Marx D, et al., Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues. Anticancer Res 1997; 17: 4299-304.
33. Garrido P, Moran J, Alonso A, et al., 17beta-estradiol activates glucose uptake via GLUT4 translocation and PI3K/Akt signaling pathway in MCF-7 cells. Endocrinology 2013; 154: 1979-89.
34. Medina RA, Meneses AM, Vera JC, et al., Estrogen and progesterone up-regulate glucose transporter expression in ZR-75-1 human breast cancer cells. Endocrinology 2003; 144: 4527-35.
35. Santalucia T, Palacin M, Zorzano A,. T3 strongly regulates GLUT1 and GLUT3 mRNA in cerebral cortex of hypothyroid rat neonates. Mol Cell Endocrinol 2006; 251: 9-16.
36. Ulisse S, Jannini EA, Pepe M, et al., Thyroid hormone stimulates glucose transport and GLUT1 mRNA in rat Sertoli cells. Mol Cell Endocrinol 1992; 87: 131-7.
37. Weinstein SP, Haber RS,. Glucose transport stimulation by thyroid hormone in ARL 15 cells: partial role of increased GLUT1 glucose transporter gene transcription. Thyroid 1993; 3: 135-42.
38. Torrance CJ, Usala SJ, Pessin JE, et al., Characterization of a low affinity thyroid hormone receptor binding site within the rat GLUT4 gene promoter. Endocrinology 1997; 138: 1215-23.
39. Moeller LC, Cao X, Dumitrescu AM, et al., Thyroid hormone mediated changes in gene expression can be initiated by cytosolic action of the thyroid hormone receptor beta through the phosphatidylinositol 3-kinase pathway. Nuclear Receptor Signal 2006; 4: e020.
40. Holzapfel HP, Bergner B, Wonerow P, Paschke R,. Expression of G(alpha)(s) proteins and TSH receptor signalling in hyperfunctioning thyroid nodules with TSH receptor mutations. Eur J Endocrinol 2002; 147: 109-16.
41. Deokant BS, Sinha MP,. Alteration of thyroid hormone profile as a biomarker of carcinogenesis. Global Journal of Bio-science and Biotechnology 2012; 1: 40-4.
42. Cheng SY,. Isoform-dependent actions of thyroid hormone nuclear receptors: lessons from knockin mutant mice. Steroids 2005; 70: 450-4.
43. Itoh Y, Esaki T, Kaneshige M, et al., Brain glucose utilization in mice with a targeted mutation in the thyroid hormone alpha or beta receptor gene. Proc Natl Acad Sci USA 2001; 98: 9913-8.
44. Romero R, Casanova B, Pulido N, et al., Stimulation of glucose transport by thyroid hormone in 3T3-L1 adipocytes: increased abundance of GLUT1 and GLUT4 glucose transporter proteins. J Endocrinol 2000; 164: 187-95.
45. Lee CH, Olson P, Hevener A, et al., PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 2006; 103: 3444-9.
46. Cao M, Long Y, Tong Y, et al., Activation of PPARdelta up-regulates the expression of insulin gene transcription factor MafA and ameliorates glucose-induced insulin secretion impaired by palmitate. Mol Cell Biochem 2012; 366: 183-9.
47. Hallakou S, Doare L, Foufelle F, et al., Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 1997; 46: 1393-9.
48. Nasri H, Behradmanesh S, Maghsoudi AR, et al., Efficacy of supplementary vitamin D on improvement of glycemic parameters in patients with type 2 diabetes mellitus; a randomized double blind clinical trial. J Renal Injury Prevent 2014; 3: 31-4.
49. Hunter J, Kassam A, Winrow CJ, et al., Crosstalk between the thyroid hormone and peroxisome proliferator-activated receptors in regulating peroxisome proliferator-responsive genes. Mol Cell Endocrinol 1996; 116: 213-21.
50. Miyamoto T, Kaneko A, Kakizawa T, et al., Inhibition of peroxisome proliferator signaling pathways by thyroid hormone receptor. Competitive binding to the response element. J Biol Chem 1997; 272: 7752-8.
51. Araki O, Ying H, Furuya F, Zhu X, Cheng SY,. Thyroid hormone receptor beta mutants: Dominant negative regulators of peroxisome proliferator-activated receptor gamma action. Proc Natl Acad Sci USA 2005; 102: 16251-6.
52. Gbaguidi GF, Agellon LB,. The inhibition of the human cholesterol 7alpha-hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated via the liver x receptor alpha and peroxisome proliferator-activated receptor alpha heterodimer. Nucleic Acids Res 2004; 32: 1113-21.
53. Boergesen M, Pedersen TA, Gross B, et al., Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor alpha in mouse liver reveals extensive sharing of binding sites. Mol Cell Biol 2012; 32: 852-67.
54. Sachdev D, Yee D,. The IGF system and breast cancer. Endocr Relat Cancer 2001; 8: 197-209.
55. Thorne JL, Maguire O, Doig CL, et al., Epigenetic control of a VDR-governed feed-forward loop that regulates p21((waf1/cip1)) expression and function in non-malignant prostate cells. Nucleic Acids Res 2011; 39: 2045-56.
56. Doig CL, Singh PK, Dhiman VK, et al., Recruitment of NCOR1 to VDR target genes is enhanced in prostate cancer cells and associates with altered DNA methylation patterns. Carcinogenesis 2013; 34: 248-56.
57. Singh PK, Doig CL, Dhiman VK, et al., Epigenetic distortion to VDR transcriptional regulation in prostate cancer cells. J Steroid Biochem Mol Biol 2013; 136: 258-63.
58. Abedin SA, Banwell CM, Colston KW, et al., Epigenetic corruption of VDR signalling in malignancy. Anticancer Res 2006; 26: 2557-66.
59. Abedin SA, Thorne JL, Battaglia S, et al., Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. Carcinogenesis 2009; 30: 449-56.
60. Battaglia S, Maguire O, Thorne JL, et al., Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion. Carcinogenesis 2010; 31: 1650-60.
61. Furuya F, Guigon CJ, Zhao L, et al., Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling. Mol Cell Biol 2007; 27: 6116-26.
62. Frasor J, Danes JM, Funk CC, et al., Estrogen down-regulation of the corepressor N-CoR: Mechanism and implications for estrogen derepression of N-CoR-regulated genes. Proc Natl Acad Sci USA 2005; 102: 13153-7.
63. Dunlop TW, Vaisanen S, Frank C, et al., The genes of the coactivator TIF2 and the corepressor SMRT are primary 1alpha,25(OH)2D3 targets. J Steroid Biochem Mol Biol 2004; 89: 257-60.
64. Mathupala SP, Ko YH, Pedersen PL,. Hexokinase-2 bound to mitochondria: cancer's stygian link to the «Warburg Effect» and a pivotal target for effective therapy. Semin Cancer Biol 2009; 19: 17-24.
65. Panasyuk G, Espeillac C, Chauvin C, et al., PPARgamma contributes to PKM2 and HK2 expression in fatty liver. Nat Commun 2012; 3: 672.
66. Dong B, Saha PK, Huang W, et al., Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc Natl Acad Sci USA 2009; 106: 18831-6.
67. Onishi A, Peng GH, Poth EM, et al., The orphan nuclear hormone receptor ERRbeta controls rod photoreceptor survival. Proc Natl Acad Sci USA 2010; 107: 11579 -, 84,.
68. Tennessen JM, Baker KD, Lam G, et al., The Drosophila estrogen-related receptor directs a metabolic switch that supports developmental growth. Cell Metab 2011; 13: 139-48.
69. Hennessy BT, Smith DL, Ram PT, et al., Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4: 988-1004.
70. Robey RB, Hay N,. Is Akt the «Warburg kinase»?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 2009; 19: 25-31.
71. Defour A, Dessalle K, Castro Perez A, et al., Sirtuin 1 regulates SREBP-1c expression in a LXR-dependent manner in skeletal muscle. PloS One 2012; 7: e43490.
72. Rempel A, Mathupala SP, Perdersen PL,. Glucose catabolism in cancer cells: regulation of the Type II hexokinase promoter by glucose and cyclic AMP. FEBS Lett 1996; 385: 233-7.
73. Mitro N, Mak PA, Vargas L, et al., The nuclear receptor LXR is a glucose sensor. Nature 2007; 445: 219-23.
74. Vigushin DM, Dong Y, Inman L, et al., The nuclear oxysterol receptor LXRalpha is expressed in the normal human breast and in breast cancer. Med Oncol 2004; 21: 123-31.
75. Wang JH, Tuohimaa P,. Calcitriol and TO-901317 interact in human prostate cancer LNCaP cells. Gene Regul Syst Biol 2008; 2: 97-105.
76. Thorne JL, Long M, Russell J, et al., Cooperative behavious of the Nuclear Receptor Superfamily ands its deregulation in Prostate Cancer. Carcinogenesis 2014; 35: 262-71.
77. Yu C, Markan K, Temple KA, et al., The nuclear receptor corepressors NCoR and SMRT decrease PPARgamma transcriptional activity and repress 3T3-L1 adipogenesis. J BiolChem 2005; 280: 13600-5.
78. Banwell CM, O'Neill LP, Uskokovic MR, et al., Targeting 1alpha,25-dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors. J Steroid Biochem Mol Biol 2004; 89: 245-9.
79. Banwell CM, Singh R, Stewart PM, et al., Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation. Recent Results Cancer Res 2003; 164: 83-98.
80. Banwell CM, Maccartney DP, Guy M, et al., Altered nuclear receptor corepressor expression attenuates vitamin d receptor signaling in breast cancer cells. Clin Cancer Res 2006; 12: 2004-13.
81. Gommersall LM, Khanim FL, Peehl DM, et al., Epigenetic repression of transcription by the Vitamin D3 receptor in prostate cancer cells. J Steroid Biochem Mol Biol 2004; 89: 251-6.
82. Khanim FL, Gommersall LM, Wood VH, et al., Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene 2004; 23: 6712-25.
83. Pommier AJ, Alves G, Viennois E, et al., Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. Oncogene 2010; 29: 2712-23.
84. Duran-Sandoval D, Mautino G, Martin, et al., Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004; 53: 890-8.
85. Swales KE, Korbonits M, Carpenter R, et al., The farnesoid x receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res 2006; 66: 10120-6.
86. Kim I, Morimura K, Shah Y, et al., Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007; 28: 940-6.
87. Journe F, Durbecq V, Chaboteaux C, et al., Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients. Breast Cancer Res Treat 2009; 115: 523-35.
88. Calabrese C, Iommarini L, Kurelac I, et al., Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells. Cancer Metab 2013; 1: 11.
89. Dawson DM, Goodfriend TL, Kaplan NO,. Lactic dehydrogenases: functions of the two types rates of synthesis of the two major forms can be correlated with metabolic differentiation. Science 1964; 143: 929-33.
90. Brown NJ, Higham SE, Perunovic B, et al., Lactate dehydrogenase-B is silenced by promoter methylation in a high frequency of human breast cancers. PloS One 2013; 8: e57697.
91. Dang CV,. MYC on the path to cancer. Cell 2012; 149: 22-35.
92. Mirebeau-Prunier D, Le Pennec S, Jacques C, et al., Estrogen-related receptor alpha modulates lactate dehydrogenase activity in thyroid tumors. PloS One 2013; 8: e58683.
93. Summermatter S, Santos G, Perez-Schindler J, et al., Skeletal muscle PGC-1 alpha controls whole-body lactate homeostasis through estrogen-related receptor alpha-dependent activation of LDH B and repression of LDH A. Proc Natl Acad Sci USA 2013; 110: 8738 -, 43,.
94. Gan ZJ, Burkart-Hartman EM, Han DH, et al., The nuclear receptor PPAR beta/delta programs muscle glucose metabolism in cooperation with AMPK and MEF2. Gene Dev 2011; 25: 2619-30.
95. Li X, Qin C, Burghardt R, et al., Hormonal regulation of lactate dehydrogenase-A through activation of protein kinase C pathways in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2004; 320: 625-34.
96. Barnett DH, Sheng S, Charn TH, et al., Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. Cancer Res 2008; 68: 3505-15.
97. Neri D, Supuran CT,. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011; 10: 767-77.
98. Parks SK, Chiche J, Pouyssegur J,. pH control mechanisms of tumor survival and growth. J Cell Physiol 2011; 226: 299-308.
99. Luo J, Manning BD, Cantley LC,. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4: 257-62.
100. Paweletz CP, Charboneau L, Bichsel VE, et al., Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20: 1981-9.
101. Paweletz CP, Liotta LA, Petricoin EF III,. New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. Urology 2001; 57: 160-3.
102. Stal O, Perez-Tenorio G, Akerberg L, et al., Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 2003; 5: R37-R44.
103. Brugarolas JB, Vazquez F, Reddy A, et al., TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003; 4: 147-58.
104. Skeen JE, Bhaskar PT, Chen CC, et al., Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 2006; 10: 269-80.
105. Kim JW, Dang CV,. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66: 8927-30.
106. Semenza GL, Roth PH, Fang HM, et al., Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994; 269: 23757-63.
107. Jones RG, Plas DR, Kubek S, et al., AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. MolCell 2005; 18: 283-93.
108. Gray IC, Stewart LM, Phillips SM, et al., Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer 1998; 78: 1296-300.
109. Modur V, Nagarajan R, Evers BM, et al., FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 2002; 277: 47928-37.
110. Aveyard JS, Skilleter A, Habuchi T, et al., Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999; 80: 904-8.
111. Cairns P, Evron E, Okami K, et al., Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998; 16: 3215-18.
112. Yang J, Ren Y, Wang L, et al., PTEN mutation spectrum in breast cancers and breast hyperplasia. J Cancer Res Clin Oncol 2010; 136: 1303-11.
113. Thimmaiah KN, Easton JB, Germain GS, et al., Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. J Biol Chem 2005; 280: 31924-35.
114. Foulstone EJ, Zeng L, Perks CM, et al., Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor. Endocrinology 2013; 154: 1780-93.
115. Lee KW, Ma LQ, Liu BR, et al., Insulin-like growth factor binding protein-3 (IGFBP-3) induces apoptosis via rapid RXR alpha-dependent TR3 mitochondrial targeting in cancer cells. Pediatr Res 2003; 53: 154.
116. Dailly YP, Linkhart TA, Mohan S, et al., The human IGFBP-6 promoter is regulated by a novel complex retinoic acid response element (RARE) activated by RAR alpha, RXR alpha receptors and a CACC box binding protein in human osteoblasts. J Bone Miner Res 2000; 15: S195.
117. Furuya F, Guigon CJ, Zhao L, et al., Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling. Mol Cell Biol 2007; 27: 6116-26.
118. Furuya F, Hanover JA, Cheng SY,. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc Natl Acad Sci USA 2006; 103: 1780-5.
119. Verga Falzacappa C, Petrucci E, Patriarca V, et al., Thyroid hormone receptor TRbeta1 mediates Akt activation by T3 in pancreatic beta cells. J Mol Endocrinol 2007; 38: 221-33.
120. Furuya F, Lu C, Guigon CJ, et al., Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors. Steroids 2009; 74: 628-34.
121. Beischlag TV, Taylor RT, Rose DW, et al., Recruitment of thyroid hormone receptor/retinoblastoma-interacting protein 230 by the aryl hydrocarbon receptor nuclear translocator is required for the transcriptional response to both dioxin and hypoxia. J Biol Chem 2004; 279: 54620-8.
122. Lefebvre B, Brand C, Flajollet S, et al., Down-regulation of the tumor suppressor gene retinoic acid receptor beta2 through the phosphoinositide 3-kinase/Akt signaling pathway. Mol Endocrinol 2006; 20: 2109-21.
123. Masia S, Alvarez S, de Lera AR, et al., Rapid, nongenomic actions of retinoic acid on phosphatidylinositol-3-kinase signaling pathway mediated by the retinoic acid receptor. Mol Endocrinol 2007; 21: 2391-402.
124. Renga B, Mencarelli A, Vavassori P, et al., The bile acid sensor FXR regulates insulin transcription and secretion. Biochim Biophys Acta 2010; 1802: 363-72.
125. Rizzo G, Passeri D, De Franco F, et al., Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol 2010; 78: 617-30.
126. Gineste R, Sirvent A, Paumelle R, et al., Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol Endocrinol 2008; 22: 2433-47.
127. Pekarsky Y, Hallas C, Palamarchuk A, et al., Akt phosphorylates and regulates the orphan nuclear receptor Nur77. Proc Natl Acad Sci USA 2001; 98: 3690-4.
128. Yoo YG, Yeo MG, Kim DK, et al., Novel function of orphan nuclear receptor Nur77 in stabilizing hypoxia-inducible factor-1alpha. J Biol Chem 2004; 279: 53365-73.
129. Masuyama N, Oishi K, Mori Y, et al., Akt inhibits the orphan nuclear receptor Nur77 and T-cell apoptosis. J Biol Chem 2001; 276: 32799-805.
130. Srinivas H, Xia D, Moore NL, et al., Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. Biochem J 2006; 395: 653-62.
131. Gatenby RA, Gillies RJ,. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891-9.
132. Flier JS, Mueckler MM, Usher P, et al., Elevated levels of glucose-transport and transporter messenger-RNA are induced by Ras or Src oncogenes. Science 1987; 235: 1492-5.
133. Deblois G, Giguere V,. Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond. Nat Rev Cancer 2013; 13: 27-36.
134. Battaglia S, Maguire O, Campbell MJ,. Transcription factor co-repressors in cancer biology: roles and targeting. Int J Cancer 2010; 126: 2511-19.
135. Campbell MJ, Carlberg C, Koeffler HP,. A role for the PPARgamma in cancer therapy. PPAR Res 2008; 2008: 314974.